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Abstract
Objectives: HBV infection is a contagious disease that may 
transmit vertically from mothers to their neonates or horizontally 
by blood products and body secretions. Over 50% of Iranian 
carriers have contracted the infection perinatally, making this 
the most likely route of transmission of HBV in Iran. This study 
assesses the serologic markers of HBV in children born to HBsAg 
positive mothers who received HBIG and 3 doses of HBV vaccine.
Methods: To evaluate the effectiveness of vaccination against 
HBV, a study was conducted on 95 Children, born to hepatitis 
B surface antigen (HBsAg)-positive mothers, who had received 
Hepatitis B Immune Globulin and HBV vaccines during 2004-
2008. All children were tested for the presence of HBsAg, anti-
HBs and anti-HB core antigen (anti-HBc).
Results: Among an estimated 30000 pregnant women during the 
five year study, about 130 (0.42%) were HBV carriers. Ninety-five 
children from these mothers were enrolled in this study. Only one 
child (1.1%) was HBsAg positive, while 88.4% of children were 
Anti-HBs Positive. Eleven children (11.6%) were exposed to HBV 
as shown by the presence of anti-HBc. A significant difference was 
observed between the children’s age and Anti-HBs (p=0.0001).
Conclusion: Passive-active immunoprophylaxis of high risk babies 
was highly efficacious in preventing perinatal transmission of the 
HBV carrier state. Also, evaluation of serologic markers in HBV 
infected people is important for designing the strategies for disease 
control.
Keywords: Children; HBsAg positive mothers; Hepatitis B 
Vaccine; Hepatitis B Immunoglobulin; Anti-HBc; Anti-HBs.
Introduction
Hepatitis B virus (HBV) infection is one of the most common 
infectious diseases in the world. The global prevalence of HBV 
carriers varies widely, from high (10-20%) in southeast Asian 
and China, to intermediate (2-7%) in the Mediterranean region, 
Japan, Central Asia, and the Middle East, and low (<2%) in the 
United States, Canada, Western Europe and Australia.1 It is 
estimated that over 35% of Iranians have been exposed to HBV. 
The prevalence of hepatitis B surface antigen (HBsAg) in Iran, a 
Middle Eastern country, varies from 1.7% in Fars to over 5% in 
Sistan-Balouchestan. However, the global prevalence is lower than 
3%.2
One of the most important routes for HBV transmission is 
from asymptomatic carrier mothers to their infants. Mother to 
child transmission occurs often in the uterus or through exposure 
to blood or blood contaminated fluids at or around birth. Such 
perinatal transmission is believed to account for 35% to 50% of 
HBV carriers.3 It has been concluded that over 50% of Iranian 
carriers have contracted the infection perinataly, making this the 
most likely route of HBV transmission in Iran.2
In the Islamic Republic of Iran (I.R. Iran), mass vaccination 
of neonates against HBV infection began in 1993 as a national 
program in routine neonatal care. The program was supposed to 
affect the prevalence rate of HBV infection through the country 
and decrease the rate of infection. Therefore, a recent study in Iran 
showed that the rate of hepatitis B carriers varied between zero 
and 3.9% with an average of 1.7%.4 Also, 3.6% of the population 
was HBsAg positive, putting Khorassan among the highly affected 
areas in Iran.4,5 HBV prevalence has decreased dramatically in 
the Iranian population during the last decade.5 Generally, it is 
estimated that approximately 1.5 to 2.5 million people are suffering 
from HBV infection in I.R. Iran, and some of them are carriers 
who may unintentionally transmit the infection to others.4,5
The age at which HBV infection occurs influences the long-
term outcome and determines the primary targets of a vaccination 
program. Thus, perinatal transmission from mother to child 
soon after birth results in approximately 90% chronic carriage, 
with long-term complications of chronic hepatitis, cirrhosis 
and hepatocellular carcinoma, leading to death by middle age, 
particularly among men.5
Infected children have a 25% or greater chance of dying from 
primary hepatocellular carcinoma or liver cirrhosis.6 To eliminate 
the risk of perinatal transmission of HBsAg from mothers to their 
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infants; a program of combined active and passive immunization 
has been established.7 Infants born to HBsAg positive mothers 
are immunized at birth with Hepatitis B Immunoglobin (HBIG) 
and HBV vaccine, and then subsequent hepatitis B vaccination 
at 1 and 6 months of age.8 The effectiveness of HBIG and HBV 
vaccines vary in various parts of the world.9,10
Evaluation of Serologic markers and risk factors in HBV 
infected people is important for designing the strategies to control 
the disease. The compliance and efficacy of the immunoprophilaxis 
program have not been followed rigorously in scientific reports 
until now. This study assesses the impact of HBIG and HBV 
vaccine in children born to HBsAg positive mothers in Amol, 
Mazandaran province, Northern Iran. Children detected with 
HBsAg, Antibody to HBV surface antigen (Anti-HBs) and 
antibody to hepatitis B core antigen (Anti-HBc) were assessed.
Methods
Amol is located in Mazandaran province in the north of Iran, 
near the Caspian Sea and is home to around 400000 residents; 
accounting for approximately 0.6% of the general population 
of Iran.11 Approximately 1.65% of Amol’s inhabitants were 
persistently infected with HBV in the past.12 During the 5 years 
from 2004 to 2008, 31241 pregnant women were tested for HBsAg 
and 130 (0.42%) were detected during their pregnancy. All children 
born to HBsAg positive mothers underwent immunoprophilaxis 
and were followed for markers of HBV infection. Attempts were 
made to contact all HBsAg positive women reported to Amol 
Health Center and maternity hospital, between April 1, 2004 
and December 21, 2008. All mothers involved gave their written 
informed consent on testing their children for HBV markers and 
were enrolled into the study from September 2009.
Serum samples were taken from the attending children aged 
as follows; less than 13 months, 13-24, 25-36, 37-48 and 49-60 
months. During the 5 year-studied period from 2004 to 2008, 
of the 95 children enrolled into the study; 53 children were aged 
less than 24 months and 42 children were aged between 25 to 
60 months. The infants of mothers found to be HBsAg positive 
were given 0.5 ml Hepatitis B Immune Globulin (Talecris 
Biotherapcutics, USA) and 0.5ml HBV vaccine (Hepavax-Gene, 
Green Cross Vaccine Crop, Korea) intramuscularly at the time of 
delivery.
The second and third doses of the vaccine were injected at 1 and 
6 months of age (according to Iran’s Ministry of Health Expanded 
Program on Immunization) at the local Health Services center. 
The youngest child enrolled into the study was 9 months of age. 
All children were tested for HBsAg and for the corresponding 
antibodies (anti-HBs) and anti-HBc. An informed consent for 
testing of HBV markers in coded serum samples from the children 
was obtained from their legal guardians.
For the detection of HBsAg, anti-HBs and anti-HBc, 
commercially available enzyme immunoassay kits (BIOKIT, S. A. 
Barcelona-Spain) were used. Immunogenicity was assessed using 
anti-HBs titers 9 months after birth. A value ≥10 mIU/ml in 
terms of anti-HBs concentrations was considered to be protective 
level. Statistical analyses were done using the Chi Square (X2) 
and Fisher’s exact tests to analyze the data obtained by SPSS 
11.5 software. The differences or association with p<0.05 were 
considered statistically significant.
Results
All the expectant mothers in Amol were tested for HBsAg in 
serum and much of the data were recorded from 2004 to 2008, 
with results summarized in Table 1. Of the 130 deliveries from 
the expectant mothers, only 95 infants participated in the study. 
Therefore, 95 cases who received immunoprophylaxis during the 5 
years studied period from 2004 to 2008 participated in the study 
and their outcomes are shown in Table 2. Table 1 also shows the 
average prevalence positivity of HBsAg at delivery (0.42%).
Table 1: Yearly deliveries and expectant mothers tested for HBsAg 
in Amol, Mazandaran province, north of Iran.
Yearly Total deliveries HBsAg Positive (%)
2004 5939 24(0.40)
2005 6442 10(0.16)
2006 6315 25(0.40)
2007 6488 40(0.62)
2008 6057 31(0.51)
Total 31241 130(0.42)
Of the 95 subjects enrolled, 50.5% were male. The data showed 
that among the 95 children born to HBsAg positive mothers 
who received immunoprophylaxis, 1.05% were HBsAg positive, 
suggesting that these children were infected with HBV two years 
after birth despite immunoglubin and hepatitis B vaccine.
Table 2: Prevalence of HBV serologic markers in children born to HBsAg positive mothers by Age group.
Age group
(month)
Number of
tested
HBsAg
Positive
Anti-HBS Positive Anti-HBc Positive
No. % No. % No. % No. %
<13 11 11.6 0 0.0 11 10.0 6 54.5
13-24 42 44.2 0 0.0 40 95.2 4 9.5
25-36 22 23.2 1 45 15 68.2 0 0.0
37-48 10 10.5 0 0.0 8 80 1 10
49-60 10 10.5 0 0.0 10 100 0 0.0
Total 95 100 1 1.05 84 88.4 11 11.6
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Table 3: Prevalence of Anti-HBs in children born to HBsAg positive mothers by Anti-HBc.
Anti- HBc Anti- HBs Total
Good Responder
(≥100 mIU/ml)
Low Responder
(10-99 mIU/ml)
Non Responder
(≤10 mIU/ml)
No. % No. % No. % No. %
Negative 38 82.6 35 92.1 11 100 84 88.4
Positive 8 17.4 3 7.9 0 0.0 11 11.6
Total 46 100 38 100 11 100 95 100
)p≥0.05( 
Table 4: Responder Rate of Anti-HBs in children born to HBsAg positive mothers by Age group.
Age group
(month)
Anti- HBs Total
Good Responder
(≥100 mIU/ml)
Low Responder
(10-99 mIU/ml)
Non Responder
(≤10 mIU/ml)
No. % No. % No. % No. %
<13 9 9.5 2 2.1 0 0.0 11 11.6
13-24 26 27.4 14 14.7 2 2.1 42 44.2
25-36 2 2.1 13 13.7 7 7.4 22 23.2
37-48 4 4.2 4 4.2 2 2.1 10 10.5
49-60 5 5.3 5 5.3 0 0.0 10 10.5
Total 46 48.4 38 40 11 11.6 95 100
)p=0.0001( 
From the 94 children who were not infected, 11 (11.6%) had 
anti-HBs levels below 10 mIUml at the time of the serotest. 
Patients with Anti-HBs levels ≤10 mIU/ml were categorized as a 
Non Responders, while Anti-HBs levels between 10 and 99 mIU/
ml were categorized as low Responders and levels ≥100 mIU/ml 
were considered as Good Responders to the immunization. Eleven 
children (11.6%), had previous exposure to HBV, as demonstrated 
by the presence of anti-HBc at the time of the study (Table 3), and 
among them, 10 children were aged less than 25 months. (Table 2)
On the other hand, 84 children (98%) were not previously 
exposed to the infection, as confirmed by the absence of anti-HBc; 
thus 73 of them (86.9%) exhibited what would be considered as 
protective concentrations of anti-HBs ≥10 mIU/ml. (Table 4)(
The Fisher’s Exact test showed a significant association between 
the rate of seropositivity for anti-HBs and age group (p=0.0001). 
Thus, 42 boys (44.2%) and 42 (44.2%) girls were anti-HBs positive. 
The rate of seropositivity for anti-HBs and anti-HBc did not differ 
in neither males nor females (p=0.48).
Discussion
Hepatitis B virus (HBV) infection is the main cause of chronic 
liver disease in Iran.2,13 The epidemiology of HBV infection in Iran 
has changed during the last two decades,2 and infantile vaccination 
with high coverage is the main cause for this change.14,15
Amongst the target groups for vaccination in the current Iran 
selective program, infants born to HBsAg seropositive mothers 
are at highest risk of acquiring hepatitis B infection. Universal 
vaccination of all neonates against hepatitis B virus has been 
implemented in the Islamic Republic of Iran since 1993 (Ministry 
of Health report). The prevalence of HBsAg in children has 
decreased from 1.3 to 0.9% within 6 years of starting the Expanded 
Program on Immunization (EPI).5
Perinatal transmission of HBV from mother to infant 
occurs during the course of pregnancy or at the time of delivery. 
Approximately 5% of infants are infected in the uterus and 
approximately 95% at the time of birth. Infants born to HBsAg 
positive carrier mothers (especially in HBeAg positive cases) 
have a contracting chronic hepatitis B infection and of possible 
subsequent progression to chronic carrier state, cirrhosis and 
hepatocellular carcinoma.8
Many studies have found an association between recording 
the maternal HBV status in delivery room records and the 
timely administration of HBIG.16 Better rates of immunization 
at birth and of completion have been documented in programs 
that provided reminders to mothers to report their HBV status at 
delivery; reported maternal HBsAg status on new-born metabolic 
screening cards; provided reminders to antenatal care providers to 
report maternal HBsAg status to the delivery hospital; and those 
that have adopted computerized tracking systems for carriers and 
their children.17
When HBV vaccine and Hepatitis B hyper immunoglobulin 
were used together in the neonatal period, 94% protection was 
achieved.18 It is important to identify the children who need 
additional doses, because of the potential risk of transmission 
after the perinatal period from the mother or from other HBV 
infected household members.6-8
Hepatitis vaccination strategies may vary from one country 
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to another depending on HBV endemicity, predominant 
transmission modes of the infection, age at time of infection, and 
the availability of healthcare resources.2
In our study, 0.42% of deliveries and expectant mothers were 
HBsAg positive. However, HBsAg positivity rate differs among 
countries. In Nigeria, HBsAg positivity was found to be 11.6% 
in pregnant women; while in Sierra Leone, it was reported to be 
11.3%; 10% in Hong Kong; 0.44% in the Netherlands and in 1.4% 
Germany.19-23 HBsAg was detected in 0.63% of expectant mothers 
in Shizoka.24 Other studies in Japan reported that 1.2% of 
expectant mothers in Iwate were HBV carriers. In another study, 
the rate of HBsAg and anti-HBs in the children was reported to be 
6.5% and 93.5%, respectively.25
Our results confirm the importance of immunoprophylaxis in 
newborn babies with HBsAg-positive mothers, while documents 
show the possibility of failure of the preventive measures. In our 
study, 11 cases of perinatal transmission were observed; the causes 
of this vaccination failure were not easy to determine. Eleven 
children (11.6%) acquired the infection as revealed by the presence 
of anti-HBc.
Breakthrough infections, due to S-gene mutants of HBV, 
have occasionally been reported among children born to HBsAg-
positive mothers, but at the present time, such mutants do not 
pose a public health threat.26
Asymptomatic infection characterized by the presence of 
anti-HBc in the absence of HBsAg viremia (‘‘mild breakthrough 
infections’’) have been documented in vaccinated individuals.27 
Rates of breakthrough infections cannot easily be compared with 
other evaluations, but the rate of 1.05% seen in those tested is 
different to the rate expected from vaccine efficacy studies.28
In our study, the rate of non-responder (anti-HBs negative) 
in children was 11.6%. These children were at risk of acquiring 
infection. Whereas, in 2002, Roshan et al. reported a 6.5% 
HBsAg in children born to HBV carrier mothers and 36.6% of 
these children were anti-HBs negative (non-responder).10 In a 
study conducted by Darmiani et al. on 22 neonates from HBsAg 
positive mothers, HBsAg rate was zero.29
Several studies have revealed a much lower non-response rate 
than the rate in the current study. A study performed by Gallo et 
al. on 85 infants born to HBsAg positive mothers showed that only 
two neonates (2.4%) were non-responders.30 While Poovorawan et 
al. in 1997, reported a 3.8% non-responder rate in neonates born to 
HBsAg positive mothers.31
A previous study conducted in Iran showed an efficacy rate of 
85.7%.14 In the present study however, the figure for efficacy was 
88.4%. Another study in Iran for HBsAg, anti-HBs and anti-HBc 
in 60 children born to HBsAg positive mothers showed efficacy 
rates of 3.6%, 85.7% and 38.7%, respectively.15 A Vietnamese 
study reported 92.2% seroprotection in 53 vaccinated infants.32
Also, a 15-year study on 1030 Japanese babies born to 
HBsAg positive carrier mothers who had received hepatitis B 
immunoglobulin at birth and 2 months after as well as vaccines 
at 2, 3 and 5 months after birth reported an efficacy rate of 95.1% 
and the carrier state developed in the remaining 4.6%.24 Marino et 
al. in Canada showed the rate of HBsAg and anti-HBs in children 
born to HBsAg positive carrier mothers were 2.3%, 87.9% and 
5.1%, respectively.33
These studies demonstrated that HBsAg in children born to 
HBsAg positive mothers is different in various part of the world. 
In the current study, one case (10.5%) was HBsAg positive. In 
a study conducted by Roome et al. (1994-1997),34 and a study 
in Taiwan reported that 1.3% and 2.4% of infants were HBsAg 
carriers, respectively.35
Infants who become chronic HBV carriers despite perfect 
immunoprophylaxis may be have been infected in the uterus, their 
mothers may have a high virus load, or they may have been infected 
through vaccine-escape virus mutants.6,8 This infection may occur 
transplacentally, thus HBIG and HBV vaccine cannot prevent the 
infection.
In our study, of the 11 cases, 10 cases with anti-HBc positive 
were more than 2 years of age, and the protection level (rate of anti-
HBs) in these children was 88.4%. This rate seems lower compared 
to rates reported in other studies. Also, in all of the 11 anti-HBc 
positive children, there was no significant association between the 
rate of seropositivity for anti-HBc and anti-HBs (p³0.05).
Anti-HBc can remain for long time in children born to 
HBsAg positive mothers. However, if only anti-HBc was detected 
in children 2 years of age, the infection may become apparent at 
an earlier stage. Some researchers have reported that the lack of 
maternal antibody to hepatitis B core antigen (anti-HBc) was 
strongly correlated with the transmission of HBV infection.35,36
The results from this study, although confirmed the 
effectiveness of the anti-hepatitis B vaccination, they highlights the 
need for post-vaccination follow-up, in order to prolong protection 
and calculate the potential need for booster doses. The study 
also conveyed the importance of maintaining active surveillance 
with the aim of improving the follow-up of chronic carriers and 
sensitizing families.
Conclusion
According to the study results, passive-active immunoprophylaxis 
in high risk children was effective and it is proposed that all 
children born to HBsAg positive mothers should be immunized 
against HBV. A study with a larger sample size is recommended.
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